Daily Stock List
Rarus Technologies, Inc. (RARS)
Wallstreetlivechat, Greenbackers, Penny Stock Circle, The Stock Scout, Penny Stock Pros, PennyStockClub, StockMarketQuote.us, and 1-2-3 Stock Alerts reported earlier on Rarus Technologies, Inc. (RARS), and we are reporting on the Company, here at the QualityStocks Daily Newsletter.
Rarus Technologies, Inc. is an emerging technology company that is focusing on establishing an innovative business model intended to bridge innovative social media and e-commerce into a marketplace that connects friends, family, consumers, and vendors in new ways. In May 2012, Rarus Technologies incorporated Zngle, Inc. as the primary subsidiary and operations base for the Zngle.com licensed internet platform. The Company formerly went by the name Rarus Minerals, Inc. They changed their name to Rarus Technologies, Inc. in February 2012. Rarus Technologies is based in Henderson, Nevada. The Company lists on the OTC Markets' OTCQB.
Znlge's goal is to bridge the gap between social media and local commerce. They work with merchants to understand their core business objectives. Their commitment is to creating action plans for full online, social media, and mobile integration. Their proprietary research and trade data helps merchants define their target markets and understand vital consumer buying trends.
The design of Rarus Technologies' Zngle.com is to be a centralized Web Portal and next-generation social media website, which incorporates voice/text messaging, video email, and mobile technologies to allow consumers to access real-time information about diverse products and services through augmented proximity reality search features.
Zngle.com will offer augmented reality coupons that feature proximity alerts for specific merchants. Zngle members will receive alerts via push notification on their smartphones when they are close to a business offering a coupon. Members can redeem an offer through displaying the mobile coupon at the point of purchase.
Zngle will earn revenue through selling banner space. This will be viewable by individuals who are within the advertiser's relevant geographic location and who display the appropriate interest criteria. Zngle will gather this specific user information through tracking accessed content, 'liked' items, and profile information. Moreover, they will incorporate a bidding strategy on all banner inventories to ensure maximum revenues.
Rarus Technologies, Inc. (RARS), closed Friday's session at $0.0057, down 3.39%, on 15,000 volume with 1 trade. The average volume for the last 60 days is 209,395 and the stock's 52-week low/high is $0.0011/$0.59.
SaveDaily, Inc. (SAVY)
Stock Twiter reported earlier on SaveDaily, Inc. (SAVY), and today we choose to highlight the Company, here at the QualityStocks Daily Newsletter.
SaveDaily, Inc. is a leading provider of low cost mutual fund investing platforms used by financial institutions. SaveDaily makes it possible for banks to provide their low-income customers with quality investment services, and to do so with attractive margins. The Company is a pioneer in the field of paperless brokerage solutions. Their ultra low cost, private label platform enables banks, brokerages, and non-traditional financial service providers to offer, profitably, high-end financial services to anyone, regardless of income, account size, or activity levels. SaveDaily offers investment and record-keeping services to their intermediary partners and directly to clients through an assortment of white-labeled interfaces.
SaveDaily conducts their business through their wholly owned subsidiary, SaveDaily.com, Inc., which is headquartered in Seal Beach, California. SaveDaily.com is a Registered Investment Advisor with the Securities and Exchange Commission (SEC). SaveDaily owns their proprietary financial services platform. SaveDaily, through their financial services partners, has the capability of making virtually all mutual funds available to their clients.
Account holders can purchase shares of virtually any mutual fund, with no minimums and no transaction fees, with Save Daily. The Company provides complete 24×7 web/kiosk/ATM access for opening accounts, making investments, redeeming shares or viewing transaction histories. Clients can invest directly into their mutual fund accounts from their existing checking accounts. In addition, they can set up regularly scheduled deductions from payroll or other sources. SaveDaily's proprietary sub-accounting technology handles all tracking and reporting. This includes electronic confirmation notices, online account balances, quarterly statements, and more.
In December 2012, SaveDaily announced that they plan to enter the managed asset business using model portfolios sub-advised by a major national asset advisory firm. SAVYInvesting, the dba used by SaveDaily.com, will conduct the business. SaveDaily has hired Mr. Rod Halvorson and Mr. Richard Starr as Managing Directors. Mr. Halvorson will lead the marketing efforts, and Mr. Starr will manage the model portfolios via their sub-advisor(s).
The same technology and processes that SaveDaily.com built to serve their small-balance investor services business will be used to support the SAVYInvesting business. This highly scalable technology enables the efficient omnibus accounting and recordkeeping functions.
SaveDaily, Inc. (SAVY), closed Friday's trading at $0.27, up 35.00%, on 23,900 volume with 6 trades. The average volume for the last 60 days is 5,776 and the stock's 52-week low/high is $0.10/$1.01.
Champions Oncology, Inc. (CSBR)
UltimatePennyStock reported this month on Champions Oncology, Inc. (CSBR), BestOtc, Stock Guru did previously, and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.
Champions Oncology, Inc. engages in the development of advanced technology solutions and services to personalize the development and use of oncology drugs. Founded in 1985, they formerly went by the name Champions Biotechnology, Inc. They changed their corporate name to Champions Oncology, Inc. in April of 2011 to reflect their new focus on developing technologies to personalize the development and use of oncology drugs. Champions Oncology lists on the OTC Markets' OTCQB. The Company has their headquarters in Hackensack, New Jersey.
Champions Oncology's TumorGraft Technology Platform is a novel approach to personalizing cancer care based upon the implantation of primary human tumors in immune deficient mice. This is followed by propagation of the TumorGrafts in a manner that preserves the biological characteristics to determine the efficacy of a treatment regimen.
The Company uses this technology to offer solutions for Personalized Oncology Solutions, which guides the development of personalized treatment plans. They also use the technology to offer solutions for Translational Oncology Solutions, which assists pharmaceutical and biotechnology companies looking for personalized approaches to drug development to lower the cost and increase the speed of drug development.
In December 2012, the Company announced the expansion of their personalized oncology services into the Asian market. Champions Oncology has been developing the necessary infrastructure to begin offering their TumorGraft services via a newly established operation in Singapore.
Recently, Champions Oncology announced that they raised $9.3 million at a price of $0.50 per share in a private placement to existing and new investors. The lead investors were Battery Ventures IX, L.P., PAR Investment Partners, L.P., Harris & Harris Group, Inc., as well as members of the Company's management team.
Proceeds from the financing will be used to grow the TumorGraft bank to support the current Translational Oncology Solutions business and future biomarker development efforts. Proceeds will also be used to continue to build out the Senior Management team, initiate a validation study for the Personalized Oncology Solutions business, and for general corporate purposes.
Champions Oncology, Inc. (CSBR), closed Friday's trading session at $0.59, down 9.23%, on 24,375 volume with 5 trades. The average volume for the last 60 days is 14,744 and the stock's 52-week low/high is $0.21/$0.75.
Functional Technologies Corp. (FEB.V)
We are highlighting Functional Technologies Corp. (FEB.V) today, here at the QualityStocks Daily Newsletter.
Functional Technologies Corp. develops and commercializes proprietary, advanced yeast-based solutions to significant challenges in the food, beverage and healthcare industries. The Company is a bioindustrial enterprise focusing on providing unique and proprietary solutions to high-impact problems in these industries, by capitalizing on their core competencies in microorganism-based technologies and platforms. Functional Technologies' head office and R&D operations are in Vancouver, British Columbia. The Company lists on the TSX Venture Exchange.
Functional Technologies' platform improves the performance of innate yeast functions, and prevents the formation of naturally occurring toxins and contaminants that either affect final product quality or are classified by the World Health Organization (WHO) as probable human carcinogens. The Company's lead technologies include yeasts that prevent and reduce the formation of the foul-smelling hydrogen sulphide (H2S) and the carcinogens acrylamide and ethyl carbamate (known as urethane), by-products of food and beverage processing. These contaminants are found in many commonly consumed items. These include fermented food products and alcoholic beverages, as well as baked and fried foods.
Phyterra Yeast, Inc. is Functional Technologies' wholly owned subsidiary. Phyterra is commercializing the Company's H2S- and acrylamide-preventing yeasts in wine and other foods and beverage markets. Phyterra's foremost focus is to manage the trials and testing, and to generate commercial sales from wineries of Functional Technologies' proprietary wine yeast strains. Furthermore, Phyterra is also working with industry partners to apply their acrylamide-preventing yeast in an array of food sectors. Phyterra Yeast has their technical sales offices in Napa Valley, California.
This week, Functional Technologies announced that Mr. Maurice Boucher joined the Company's in-house Investor Relations department to enhance their communication and reporting to Functional Technologies' shareholders and to the Canadian and International investment communities.
Mr. Boucher has extensive experience providing Investor Relations and Corporate Finance services for pre-revenue technology companies in Canada and the United States over the past 23 years. He is a Founder, Board member and CFO of a successful hi-tech company based in China.
Functional Technologies Corp. (FEB.V), closed Friday's trading session at $0.165, down 8.33%, on 58,952 volume. The stock's 52-week low/high is $0.13/$0.45.
Nemaska Lithium, Inc. (NMX.V)
BabyBulls reported previously on Nemaska Lithium, Inc. (NMX.V), and we highlight the Company, here at the QualityStocks Daily Newsletter.
Trading on the TSX Venture Exchange, Nemaska Lithium, Inc. is an exploration and development company focusing on the development of their 100 percent owned Whabouchi lithium deposit. A Preliminary Economic Assessment (PEA) was filed on January 19, 2011 for Whabouchi. The Company has lithium/berylium properties located in the James Bay region of Quebec. Nemaska Lithium is also an important shareholder of Monarques Resources, Inc. (MQR.V). Nemaska Lithium's shares also trade on the OTCQX International under the trading symbol NMKEF.
Nemaska Lithium's intention is to become a lithium hydroxide/carbonate producer based in Quebec. The Company has the aforementioned Whabouchi as well as their Sirmac lithium deposits in Quebec. The Whabouchi lithium deposit is situated near the Cree community of Nemaska and the Nemiscau airport. The Company's Whabouchi deposit is the second richest deposit in the world. The expectation is that the mine will produce approximately 213,000 tonnes of spodumene concentrate each year, which will undergo transformation into approximately 20,700 tonnes of lithium hydroxide and approximately 10,000 tonnes of lithium carbonate, both of battery grade.
The Company has filed patent applications for their proprietary method to produce lithium hydroxide and lithium carbonate. Nemaska intends to build a Phase I lithium hydroxide plant using their proprietary chemical transformation process. Their lithium hydroxide/carbonate processing plant will be in Salaberry-de-Valleyfield, Quebec. The plant has been designed with the flexibility to produce 27,000 tonnes of lithium hydroxide and 4,000 tonnes of lithium carbonate should the market demand for hydroxide outpace lithium carbonate.
Yesterday, Nemaska Lithium confirmed that the Company is proceeding with the building of their Phase 1, maximum 500t/year capacity, lithium hydroxide and carbonate processing plant in Salaberry-de-Valleyfield, Quebec. Met-Chem Canada, Inc. (Met-Chem) has prepared a construction and installation budget of $25 million. The budget includes engineering, procurement, construction management and a contingency of 15 percent.
The Company is considering financing options that include a combination of equity and debt. The current schedule, prepared by Met-Chem, calls for the Phase 1 plant to be commissioned during the month of December 2013 with production starting in January 2014. Nemaska has signed an off-take agreement (announced October 3rd, 2012) with Phostech Lithium of Candiac, Quebec, for the supply of up to 500 t/y of lithium hydroxide.
Nemaska Lithium, Inc. (NMX.V), closed Friday's trading session at $0.465, down 3.12%, on 63,650 volume. The stock's 52-week low/high is $0.32/$0.65.
Interleukin Genetics, Inc. (ILIU)
MicroCap Gems and FeedBlitz reported previously on Interleukin Genetics, Inc. (ILIU), and we are reporting on the Company today, here at the QualityStocks Daily Newsletter.
Interleukin Genetics, Inc. is a genetics-focused personalized health company with headquarters in Waltham, Massachusetts. The Company develops and markets a line of genetic tests under the Inherent Health® and PST brands®. These products enable individuals to prevent certain chronic conditions as well as manage their existing health and wellness by way of genetic-based insights with actionable guidance. Founded in 1986, Interleukin Genetics operates an on-site, state-of-the-art DNA testing laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). The Company lists on the OTC Markets' OTCQB.
Interleukin Genetics leverages their research, intellectual property (IP) and genetic panel development expertise in metabolism and inflammation to facilitate the emerging personalized healthcare market. They market their tests via partnerships with health and wellness companies, healthcare professionals and other distribution channels.
The Company has research collaborations with Stanford University, University of Sheffield, Tufts University, New York University, Harvard University, the Mayo Clinic, California Pacific Medical Center, Boston University, the University of Arkansas, Tongji Medical College, University of North Carolina, and Yonsei University for the development of their genetic risk assessment tests and other products.
Their flagship products include their proprietary PST® genetic risk panel for periodontal disease and tooth loss susceptibility sold through dentists. The PST® Genetic Susceptibility Test is the first and only genetic test that analyzes two interleukin 1 (IL1) genes for variations that identify an individual's predisposition for over-expression of inflammation and risk for periodontal disease.
Additionally, the Company's flagship products include the Inherent Health Weight Management Genetic Test. It identifies the most effective diet and exercise program for an individual based on genetics. The Weight Management Test offers a genetics-based program that will determine whether an individual is likely to benefit more from a low fat, low carbohydrate or balanced calorie reduced diet, and whether one is likely to obtain more benefit from normal or more vigorous exercise to most efficiently lose weight.
Last month, Interleukin Genetics announced the appointment of Mr. Scott Snyder as Chief Marketing Officer. In this role, Mr. Snyder will lead the launch of the Company's proprietary PST® genetic risk panel to guide more effective dental preventive care. He will have responsibility for marketing their professional healthcare tests, including PST® and a proprietary test for osteoarthritis progression, and for the Inherent Health® brand of health and wellness genetic tests within consumer channels.
Interleukin Genetics, Inc. (ILIU), closed Friday at $0.40, even for the day, on 112,605 volume with 8 trades. The average volume for the last 60 days is 9,820 and the stock's 52-week low/high is $0.22/$0.55.
Savient Pharmaceuticals, Inc. (SVNT)
Bull in Advantage, Stock Analyzer, Penny Stock Rumble, The Street, StreetInsider, PennyTrader Publisher, SmarTrend Newsletters, TopStockAnalysts, StreetAuthority Daily, StockHideout, FeedBlitz, and Real Pennies reported earlier on Savient Pharmaceuticals, Inc. (SVNT), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company whose shares trade on the NASDAQ Global Market. The Company is focusing on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients who do not respond to conventional therapy. Savient also supplies Oxandrin® (oxandrolone tablets, USP) CIII in the United States. The Company has their corporate headquarters in Bridgewater, New Jersey.
Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA® and its uses from Duke University and Mountain View Pharmaceuticals, Inc. Duke developed the recombinant uricase enzyme and Mountain View developed the PEGylation technology used in the manufacture of KRYSTEXXA®. Mountain View and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology. Savient Pharmaceuticals owns or co-owns U.S. and foreign patents and patent applications, which collectively form an extensive portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA®.
KRYSTEXXA® received approval in the United States in September 2010. KRYSTEXXA® is indicated in the U.S. for the treatment of chronic gout in adult patients' refractory to conventional therapy. KRYSTEXXA® is not recommended for the treatment of asymptomatic hyperuricemia.
KRYSTEXXA® (pegloticase) is a PEGylated uric acid specific enzyme for administration by intravenous infusion. The active substance pegloticase is a covalent conjugate of uricase produced by a genetically modified strain of Escherichia coli and monomethoxypoly (ethylene glycol).
Last month, Savient Pharmaceuticals and their wholly owned subsidiary, Savient Pharma Ireland Ltd., announced that the European Commission granted a marketing authorization for KRYSTEXXA® (pegloticase). The marketing authorization for KRYSTEXXA® is for the treatment of severe debilitating chronic tophaceous gout in adult patients who may also have erosive joint involvement and who have failed to normalize serum uric acid with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these medicines are contraindicated.
The basis of the European Commission's approval decision was on safety and efficacy data from Savient's two pivotal Phase III studies, and a long-term open label extension study of KRYSTEXXA®, as well as non-clinical and chemistry, manufacturing and control information. Savient will continue to provide KRYSTEXXA to patients through the established Named Patient Programme (NPP), until the product becomes commercially available in the European Union.
Savient Pharmaceuticals, Inc. (SVNT), closed Friday's trading session at $0.9388, up 2.04%, on 589,734 volume with 1,021 trades. The average volume for the last 60 days is 928,734 and the stock's 52-week low/high is $0.4831/$2.95.
Onteco Corp. (ONTC)
OTCPicks, Orbit Stocks, HyperSpeedStocks, OtcWizard, PennyTrader Publisher, Penny Stock Rumble, Stock Exploder, Pumps and Dumps, PSSMS Newsletter and Greenbackers reported earlier on Onteco Corp. (ONTC), and we highlight the Company, here at the QualityStocks Daily Newsletter.
Founded in 2007 and listed on the OTCQB, Onteco Corp. established to develop innovative, practical and cost-effective solutions to some of the most significant environmental challenges facing industries and governments globally. In addition, these solutions must show promise of generating profits for the Company. Specifically, Onteco has determined that one industry that meets both of these points of criteria is the Energy Saving Lighting Industry. Therefore, the Company acquired NexPhase Lighting, Inc., in February of 2011. Onteco is based in Aventura, Florida.
Through their subsidiaries, joint ventures, and business partners, Onteco's mission is to continue to invest in, develop, nurture, and bring to market, innovative, practical, and cost-effective solutions to everyday environmental and alternative energy needs. The Company's NexPhase Lighting designs, develops, manufactures and markets a high quality and high efficiency full line of LED intelligent lighting fixtures and control systems for commercial applications and projects involving new construction and retrofits.
All NexPhase lighting products incorporate their proprietary "NexSense Technology™". NexSense control systems use a unique, "patent pending" wireless protocol. It provides for substantial reduction in architecture and infrastructure installation cost in commercial applications, and significantly reduced maintenance and ongoing operation costs.
The LED Lighting Fixtures include downlight troffer; reflective troffer, which adds an architectural flair to any space, and high-bay fixtures, which provide a 50-70 percent energy savings over metal halide and high-pressure sodium high bays. LED Lighting Fixtures also include
low-bay and parking garage fixtures, which also provide a 50-70 percent savings over metal halide and high pressure sodium high bays; MR-16 lamps with approximate 90 percent energy savings over conventional MR-16 with significantly less heat, as well as PAR 38 lamps with approximately 90 percent energy savings over conventional MR-16 with substantially less heat.
Effective October 25, 2012, Onteco's Board of Directors approved and authorized the execution of a share exchange agreement with Cyber Centers Worldwide Corp., a private Florida corporation (CCWC), and the shareholders of CCWC. In accordance with the terms and provisions of the Share Exchange Agreement, the Company will acquire approximately 150,000,000 shares of common stock of CCWC and 1,000,000 shares of Series B preferred stock of CCWC. This represents 100 percent of the total issued and outstanding shares held of record by the CCWC Shareholders.
In exchange for the acquisition of the capital shares of CCWC, Onteco shall issue to the CCWC Shareholders on a pro rata basis 150,000,000 restricted shares of common stock of Onteco and 1,000,000 shares of Series B preferred stock of the Company. This resulted in CCWC becoming the wholly owned subsidiary of Onteco. Before this share exchange, CCWC changed their name from Cyber Centers International Corp.
Onteco Corp. (ONTC), closed Friday's session at $0.0001, even for the day, on 12,788,185 volume with 9 trades. The average volume for the last 60 days is 18,780,911 and the stock's 52-week low/high is $0.0001/$0.175.
Consorteum Holdings, Inc. (CSRH)
The QualityStocks Daily Newsletter would like to spotlight Consorteum Holdings, Inc. (CSRH). Today, Consorteum Holdings, Inc. closed trading at $0.017, up 25.93%, on 409,574 volume with 9 trades. The stock’s average daily volume over the past 60 days is 123,504, and its 52-week low/high is $0.001/$0.02.
Consorteum Holdings, Inc. (CSRH) utilizes the most technically advanced global solutions available today. By working with a multitude of global technologies, Consorteum is able to create customized programs for maximum results. This approach enables unparalleled flexibility when sourcing solutions, resulting in smarter, faster deployment of technologies, competitive pricing, and potential for new streams of revenue.
Through its exclusive software license with Tarsin Inc., the company leverages a team of software developers that understands the complexities of delivering digital media content across mobile handsets. Tarsin is capable of providing clients with integration and support for over 700 mobile carriers globally on a seamless and secure platform to take advantage of the increasing demand for rich mobile content.
Consorteum's flagship CAPSA technology platform brings a universal solution to the problems of wagering and betting on mobile devices. Multiple different operating systems, user interfaces, and form factors have created enormous barriers to launching commercial initiatives. But with CAPSA, gaming operators can now cost-effectively monetize innovative mobile wagering products and services quickly and robustly.
In addition to its mobile initiatives, Consorteum is also actively engaged in the financial industry, providing MasterCard solutions as well as loyalty and reward programs. The company has strategically designed its business initiatives to create repetitive transactions on an ongoing basis. Consorteum's goal is to have their customers think of them more as partners, rather than just technology providers, for longer-lasting, more profitable relationships. Disclaimer
Consorteum Holdings, Inc. Company Blog
Consorteum Holdings, Inc. News:
Consorteum Holdings Files Form 10-K Report With the Securities and Exchange Commission
CORRECTION -- Tarsin, a Leader in Secure Mobile Platform Technology, Forges New Frontiers in Mobile Gaming
Tarsin, a Leader in Secure Mobile Platform Technology, Forges New Frontiers in Mobile Gaming
Bergamo Acquisition Corp. (BGMO)
The QualityStocks Daily Newsletter would like to spotlight Bergamo Acquisition Corp. (BGMO). Today, Bergamo Acquisition Corp. closed trading at $0.0497, up 24.25%, on 54,108 volume with 4 trades. The stock’s average daily volume over the past 60 days is 175,960, and its 52-week low/high is $0.01/$0.07.
Bergamo Acquisition Corp. (BGMO) is a global investor targeting a diversified portfolio of large corporate and middle-market companies for sole acquisition and co-investment alongside other sophisticated investors such as private equity funds, hedge funds, investment banks, and other institutions. The company has engaged investments in financial instruments and companies worldwide.
Alternative energy is a key focus of the company. Bergamo Acquisition has developed solar generators for cell phone towers, solar generators for home and industry applications, and solar operated tube well water pumping systems to meet the vast needs of emerging markets. The company’s turnkey solutions help developers, utilities, water districts, power plant owners, and industrial customers diversify their existing generation portfolio.
Bergamo Acquisition executes energy projects from concept through completion, offering design, construction management, and facility maintenance services. Together with pre-designed and packaged Balance of Plant and standardized Power Plant Control Modules, the company enables rapid project commissioning and provides an optimum balance between capital cost, plant performance, and operational and maintenance expenses.
The company’s technical team has been working with government officials, manufactures, and importers in Asia, Africa, and the Middle East to introduce its state-of-the-art technology. Investable funds are already in place to pursue investment opportunities in these and other countries. Bergamo Acquisition relies on its extensive network within the global institutional investment and banking industries to source the best opportunities. Disclaimer
Bergamo Acquisition Corp. Company Blog
Bergamo Acquisition Corp. News:
Bergamo Acquisition Corp. Provides Authenticated Documentation to Confirm Bank Deposits
L.L. Bradford Letter Confirms Funding Reported by Bergamo Acquisition Corp.
Bergamo Acquisition Corp. Signs Investment Agreement
International Stem Cell Corp. (ISCO)
The QualityStocks Daily Newsletter would like to spotlight International Stem Cell Corp. (ISCO). Today, International Stem Cell Corp. closed trading at $0.38, up 5.26%, on 194,832 volume with 40 trades. The stock’s average daily volume over the past 60 days is 211,020, and its 52-week low/high is $0.161/$0.65.
International Stem Cell Corp. (ISCO) specializes in the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. The company was first to perfect the natural phenomenon of parthenogenesis, which utilizes unfertilized human eggs to create hpSCs. These stem cells, created in a particular form called HLA homozygous, can be immune-matched to millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.
hpSCs are as pluripotent as embryonic stem cells (ESCs) and have significant therapeutic potential but their creation does not involve the destruction of a viable human embryo – thus sidestepping the controversy and ethical dilemmas associated with the use of human embryonic stem cells. Different from induced pluripotent stem cells (iPSs), hpSCs do not involve manipulation of gene expression back to a less differentiated stage – a practice that may become a safety or regulatory obstacle in clinical applications.
A relatively small number of hpSC lines can offer the potential of producing the first true stem cell bank, UniStemCell, which ISCO intends to create as a means of serving populations across the globe. The company's scientists are currently focused on using hpSC to treat severe diseases of the eye, nervous system, and liver, for which cell therapy has been clinically proven but is limited due to the unavailability of safe human cells.
In addition to its therapeutic focus, ISCO also provides two revenue streams. Firstly through its subsidiary Lifeline Cell Technology, specialized cells and growth media for biological research around the world, and secondly its subsidiary Lifeline Skin Care, the company manufactures and sells anti-aging skincare products utilizing an extract from the hpSC and by leveraging the latest discoveries in the fields of stem cell biology, nanotechnology, and skin cream formulation technology. Disclaimer
International Stem Cell Corp. Company Blog
International Stem Cell Corp. News:
International Stem Cell Corporation Announces Positive Results From In Vivo Animal Study of Parkinson's Disease
International Stem Cell Corporation Announces Positive Animal Efficacy Results in Liver Disease Program
International Stem Cell Corporation to Participate in Biotech Showcase 2013 on January 7th
Rainbow Coral Corp. (RBCC)
The QualityStocks Daily Newsletter would like to spotlight Rainbow Coral Corp. (RBCC). Today, Rainbow Coral Corp. closed trading at $0.43, up 4.88%, on 111,600 volume with 42 trades. The stock’s average daily volume over the past 60 days is 90,583, and its 52-week low/high is $0.27/$2.67.
Rainbow Coral Corp. (RBCC), via wholly owned subsidiary Rainbow Biosciences, continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. The company specifically pursues opportunities that offer short-term marketability and commercialization potential in key areas like Alzheimer's, Parkinson's, and Cancer.
Bioscience technology is a growing, dynamic field of innovation that applies life processes to practical uses, such as the manufacturing of medical devices and the development of new bioscience procedures. From pharmaceuticals to pacemakers, genetically engineered plants to gene therapy, bioscience technology can be found virtually anywhere.
The pending joint venture with Amarantus BioScience to develop and market new therapies and treatments for neurological diseases and physical traumas is a great example of the initiatives underway. In recent news, Amarantus licensed a highly promising diagnostic blood test that could become an invaluable new tool in Alzheimer's clinical trials where patient recruitment errors occur often due to inaccurate diagnosis.
The global biotech industry, currently valued at more than $84.6B, allows new players with bright ideas to quickly grab market share and create completely new markets. The exciting initiatives being driven forward by Rainbow Coral promise to transition today's leading-edge research into practical, affordable treatments for people who need them most. Disclaimer
Rainbow Coral Corp. Company Blog
Rainbow Coral Corp. News:
RBCC: n3D Technology Could Lead to Lab-Grown Implantable Organs
RBCC Partner N3D Could Revolutionize Toxicity Testing
RBCC Visits Texas Genome-Mapping Target
Poly Shield Technologies has named Rasmus Norling as the company’s CEO, president, and a director, effective February 6, 2013. Norling succeeds Mitchell Miller, who resigned as CEO and president February 6, 2013; Miller will remain as a director of the company.
Prior to his appointment as a Poly Shield executive, Norling served as manager of R&D of Marine Technical Services at Royal Caribbean International Ltd. for nearly 13 years. During his employment at Royal Caribbean, Norling also held positions as manager of R&D of Environmental Technologies and of Energy Optimization; ship manager of Marine Operations; and chief engineer.
Norling holds a marine engineer degree from Högskolan i Kalmar, the maritime academy at Kalmar, Sweden.
Norling is also the inventor of a fuel desalination scrubber with patents pending in the U.S. and Europe, further reflecting his value to Poly Shield, which is focused on the research, development, and marketing of environmental, pollution emissions, energy saving, corrosion, and durability solutions.
The terms of Norling’s employment agreement with Poly Shield include his deliverance to the company certain minimum technology rights. The company noted this delivery has been fulfilled.
“Rasmus, with his expertise in the development of environmental and pollution emissions solutions, is the right person to lead our company as we proceed to meet our ever increasing market demands for innovative technologies worldwide,” John da Costa, director and CFO of Poly Shield stated in the press release.
For more information, visit www.polyshieldtechnologies.com
Terra Tech, a leader in sustainable agricultural products, is pleased to announce that GroRite, a New Jersey based urban agricultural retail supercenter was named as Today’s Garden Center’s Revolutionary 100 Garden Centers for 2013. GroRite has grown into one of New Jersey’s premier gardening centers with annual revenue in excess of $4 Million.
The Revolutionary 100 Awards focus on recognizing the most innovative retail garden centers for their commitment to creating a customer experience that sets their operation apart from the rest. Today’s Garden Center utilizes a competitive and lengthy review process when determining its winners.
“We have worked hard to revolutionize the way people view a gardening center,” explains Ken Vande Vrede, CEO of GroRite. “Traditional retail outlets are a thing of the past as consumers are demanding a broader range of products, as well as new technologies for cultivating such as hydroponics.”
In addition, GroRite retail center will add Terra Tech’s line of hydroponic equipment to its shelves giving shoppers access to some of the most innovative and affordable urban gardening products on the market today. Terra Tech has a letter of Intent to acquire GroRite and the two entities are working aggressively to finalize the terms.
“Recognition like this speaks volumes that we made a great choice in pursuing an acquisition of GroRite,” explains Derek Peterson, CEO of Terra Tech. “We are looking forward to replicating their model in other locations throughout the US.”
Today, POZEN presented data from the combined results of two Phase 3 studies of PA32540 in patients with prior cerebrovascular disease. PA32540 is an antiplatelet therapy of enteric-coated (EC) and immediate-release omeprazole. Data from the two studies was presented as poster board No. MP103 on Feb. 7 at the American Heart Association 2013 International Stroke Conference in Honolulu, Hawaii.
The studies found that in the post-hoc analysis of subjects with a history of transient ischemic attack (TIA) or stroke, receiving long-term treatment (six months) of PA32540, as compared with EC-ASA (325 mg), was associated with a substantially reduced rate of endoscopic gastroduodenal ulcers (2.0 percent versus 12.4 percent, respectively; p=0.005) as well as a reduction in study discontinuation due to adverse pre-specified upper GI events (0 percent versus 8.0 percent, respectively; p=0.006). The incidence of adjudicated major adverse cardiac events was similar for PA32540 (2.9 percent) and EC-ASA (325 mg) (4.4 percent).
As stated in the AHA guidelines, using an antiplatelet agent, like aspirin, is recommended for reducing the risk of recurrent stroke and other cardiovascular events. Adherence to aspirin therapy saves patients’ lives, while discontinuing aspirin increases the likelihood of potential adverse cardiovascular and cerebrovascular events; however, aspirin therapy is often discontinued due to aspirin’s adverse GI effects. In these pivotal studies, PA32540 was shown to have a significantly lower incidence of treatment discontinuation than use of aspirin alone.
A progressive pharmaceutical company that is changing the way the healthcare industry addresses unmet medical needs, POZEN has successfully developed and obtained FDA approval for two self-invented products in two years by utilizing an in-source model and focusing on integrated therapies. Funded by these milestone/royalty streams, the company is developing a portfolio of cost-effective, evidence-based integrated aspirin therapies that are designed to reduce the GI damage of aspirin to enable its full treatment power. The company is presently seeking strategic partners to help maximize the opportunity for its portfolio assets.
For more information, visit www.pozen.com
Leading M2M connectivity service provider Lantronix announced that its xPrintServer™—Office Edition won MacObserver’s Editor’s Choice Award during Macworld | iWorld 2013. The xPrintServer—Office Edition is designed for business and IT professionals who wish to print from their iPad®, iPhone®, or iPod® to any printer.
As the industry’s first and only plug-and-print hardware solution for printing from virtually any iOS device, the xPrintServer—Office Edition offers automatic printer discovery and no configuration, making printing hassle-free. Users only have to open the box, plug in power and Ethernet, and print from an iOS device to any USB or network-connected printer, whether wired or wireless.
The xPrintServer currently supports thousands of networked printer models from leading printer families including HP, Brother, Epson, Canon, Dell, Lexmark, and Xerox. The company will announce on their website, www.latronix.com, as new printer brands and models become available.
“From ease-of-use to active directory, to the USB port and enhanced security and accounting features, the xPrintServer Office Edition makes printing throughout the enterprise a snap,” said Mark D. Tullio, Latronix’s vice president of worldwide marketing. “The xPrintServer represents Lantronix’s continuing commitment to delivering high quality, innovative, secure and easy-to-deploy solutions. We could not be more pleased to have the newest edition to the xPrintServer family recognized among so many innovative products at Macworld.”
The xPrintServer—Office Edition retails for $199.95. The xPrintServer—Home Edition, designed for home users, retails for $99.95. Both editions are also available on the company’s website, as well as a variety of e-tailers including Amazon, Best Buy Online, Buy.com, CDW, DataVision, Ebyte.com, Insight Enterprises, MacMall, Mavtechonline.com, NeutronUSA, Newegg.com, NextDayPC.com, NextWarehouse.com, PCMall, PowerMax.com, Provantage, SemiconductorStore.com, SoftwareForLess, and more.
Today's Top 3
Stocks That Move
The QualityStocks Public Company Sponsor News